2016 Fiscal Year Final Research Report
Novel anti-cancer therapeutic strategy with mTORC1/2 inhibitor against bladder cancer
| Project/Area Number |
26462428
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Urology
|
|---|
| Research Institution | Keio University |
|---|
Principal Investigator |
KIKUCHI EIJI 慶應義塾大学, 医学部(信濃町), 講師 (10286552)
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Keywords | 分子標的 / 膀胱癌 / 腎盂尿管癌 / 抗癌剤 |
|---|
| Outline of Final Research Achievements |
The following five results were obtained.
1) We found that AXL, which is in the TAM family of receptor tyrosine kinases and its ligand, Gas6 expression were the independent prognostic factors for upper tract urothelial carcinoma. 2) After exposed to nicotine, T24 bladder tumor cell growth was induced through activation of PI3K-Akt-mTOR. NVP-BEZ235 reduced the cell growth by inhibiting the activated PI3K-Akt-mTOR. 3) NVP-BEZ235 inhibited subcutaneous tumor growth and pS6 overexpression induced by nicotine. 4) The combination of cisplatin and NVP-BEZ235 had strong cytotoxic effect. 5) In an orthotopic bladder tumor model, intravesical administration of NVP-BEZ235 had a significant antitumor effect through inhibiting PI3K-Akt-mTOR pathway.
|
| Free Research Field |
膀胱癌
|
